Skip to main content
SpringerLink
Log in

Devices for Heart Failure: Implantable Cardioverter Defibrillator

  • Chapter
  • First Online:
Current Approach to Heart Failure

Abstract

Implantable cardioverter defibrillator is an implantable battery-powered device, which consists of a device and lead(s), and aimed to convert life threatening ventricular tachyarrhythmias (ventricular tachycardia, ventricular fibrillation) to a sinus rhythm by means of an antitachycardia pacing and direct biphasic current shock. The implantable cardioverter defibrillators usually have pacemaker function as an additional function.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

AF:

Atrial fibrillation

ATP:

Antitachycardia pacing

CAD:

Coronary artery disease

CRT:

Cardiac resynchronization therapy

CRT-D:

Cardiac resynchronization therapy with an ICD function

CVD:

Cardiovascular disease

HF:

Heart failure

ICD:

Implantable cardioverter defibrillator

LV:

Left ventricle

LVEF:

LV ejection fraction

QOL:

Quality of life

SCD:

Sudden cardiac death

S-ICD:

Subcutaneous implantable defibrillator

VF:

Ventricular fibrillation

VT:

Ventricular tachycardia

References

  1. Beck CS, Pritchard WH, Feil HS. Ventricular fibrillation of long duration abolished by electric shock. JAMA. 1947;135:985.

    Article  CAS  Google Scholar 

  2. Mirowski M, Reid PR, Mower MM, Watkins L, Gott VL, Schauble JF, et al. Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. N Engl J Med. 1980;303:322–4.

    Article  CAS  PubMed  Google Scholar 

  3. Mond HG, Proclemer MD. The 11th world survey of cardiac pacing and implantable cardioverter-defibrillators: calendar year 2009–a World Society of Arrhythmia's project. Pacing Clin Electrophysiol. 2011;34(8):1013–27.

    Article  PubMed  Google Scholar 

  4. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787–847.

    Article  PubMed  Google Scholar 

  5. Braunwald E. Shattuck lecture: cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med. 1997;337:1360–9.

    Article  CAS  PubMed  Google Scholar 

  6. Heart disease and stroke statistics: 2005 update. Dallas: American Heart Association; 2005.

    Google Scholar 

  7. Go AS et al. Executive summary: heart disease and stroke statistics: 2013 update—a report from the American Heart Association. Circulation. 2013;127(1):143–52.

    Article  PubMed  Google Scholar 

  8. Curtis LH, Whellan DJ, Hammill BG, et al. Incidence and prevalence of heart failure in elderly persons, 1994–2003. Arch Intern Med. 2008;168:418–24.

    Article  PubMed  Google Scholar 

  9. Roger VL, Weston SA, Redfield MM, et al. Trends in heart failure incidence and survival in a community-based population. JAMA. 2004;292:344–50.

    Article  CAS  PubMed  Google Scholar 

  10. Kannel WB. Incidence and epidemiology of heart failure. Heart Fail Rev. 2000;5(2):167–73.

    Article  CAS  PubMed  Google Scholar 

  11. Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347:1397–402.

    Article  PubMed  Google Scholar 

  12. Loehr LR, Rosamond WD, Chang PP, Folsom AR, Chambless LE. Heart failure incidence and survival from the Atherosclerosis Risk in Communities study. Am J Cardiol. 2008;101(7):1016–22.

    Article  PubMed  Google Scholar 

  13. Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K, Haase N, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O'Donnell CJ, Roger V, Rumsfeld J, Sorlie P, Steinberger J, Thom T, Wasserthiel-Smoller S, Hong Y, American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics–2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007;115:e69–e171.

    Article  PubMed  Google Scholar 

  14. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, Zheng ZJ, Flegal K, O’Donnell C, Kittner S, Lloyd-Jones D, Goff Jr DC, Hong Y, Adams R, Friday G, Furie K, Gorelick P, Kissela B, Marler J, Meigs J, Roger V, Sidney S, Sorlie P, Steinberger J, Wasserthiel-Smoller S, Wilson M, Wolf P. Heart disease and stroke statistics–2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113:e85–e151.

    Article  PubMed  Google Scholar 

  15. AbouEzzeddine OF, French B, Mirzoyev SA, et al. From statistical significance to clinical relevance: a simple algorithm to integrate brain natriuretic peptide and the Seattle Heart Failure Model for risk stratification in heart failure. J Heart Lung Transplant. 2016. pii: S1053–2498(16)00063–2.

    Google Scholar 

  16. Glikson M, Friedman PA. The implantable cardioverter defibrillator. Lancet. 2001;357:1107–17.

    Article  CAS  PubMed  Google Scholar 

  17. Gasparini M, Nisam S. Implantable cardioverter defibrillator harm? Europace. 2012;14:1087–93.

    Article  PubMed  Google Scholar 

  18. Bongiorni MG, Viani S, Zucchelli G, et al. Subcutaneous implantable cardiac defibrillators: indications and limitations. Curr Heart Fail Rep. 2015;12:79–86.

    Article  PubMed  Google Scholar 

  19. Russo AM et al. ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 appropriate use criteria for implantable cardioverter-defibrillators and cardiac resynchronization therapy: a report of the American College of Cardiology Foundation appropriate use criteria task force, Heart Rhythm Society, American Heart Association, American Society of Echocardiography, Heart Failure Society of America, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. J Am Coll Cardiol. 2013;61(12):1318–68.

    Article  PubMed  Google Scholar 

  20. Brignole M et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J. 2013;34(29):2281–329.

    Article  PubMed  Google Scholar 

  21. Priori SG, Blomstrom-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Eur Heart J. 2015;36:2793–867.

    Article  PubMed  Google Scholar 

  22. Mozaffarian D et al. Prediction of mode of death in heart failure: the Seattle Heart Failure Model. Circulation. 2007;116(4):392–8.

    Article  PubMed  Google Scholar 

  23. Packer M, Bristow MR, Cohn JN, et al. Effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349–55.

    Article  CAS  PubMed  Google Scholar 

  24. Philippe L, CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9–13.

    Google Scholar 

  25. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet. 1999;353:2001–7.

    Google Scholar 

  26. Packer M, Coats AJ, Fowler MB, Carvedilol Prospective Randomised Cumulative Survival Study (COPERNICUS) Study Group, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure. Circulation. 2002;106:2194–9.

    Article  PubMed  Google Scholar 

  27. Al-Gobari M, El Khatib C, Pilon F, Gueyffier F. Beta-blockers for the prevention of sudden cardiac death in heart failure patients: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2013;13:52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. The Antiarrhythmic Versus Implantable Defibrillator (AVID) investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near fatal ventricular arrhythmias. N Engl J Med. 1997;337:1576–83.

    Google Scholar 

  29. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH, Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–37.

    Article  CAS  PubMed  Google Scholar 

  30. Kuck KH, Cappato R, Siebels J, et al. Randomized comparison of anti-arrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000;102:748–54.

    Article  CAS  PubMed  Google Scholar 

  31. Connoly SJ, Gent M, Roberts RE, et al. Canadian implantable defibrillator study (CIDS). Circulation. 2000;101:1297–302.

    Article  Google Scholar 

  32. Connolly SJ, Hallstrom AP, Cappato R, et al. Meta analysis of ICD secondary prevention trials – AVID, CASH & CIDS. Eur Heart J. 2000;21:2071–8.

    Article  CAS  PubMed  Google Scholar 

  33. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, Levine JH, Saksena S, Waldo AL, Wilber D, Brown MW, Heo M. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996;335:1933–40.

    Article  CAS  PubMed  Google Scholar 

  34. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Multicenter Automatic Defibrillator Implantation Trial II Investigators, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–83.

    Article  PubMed  Google Scholar 

  35. Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R, Fain E, Gent M, Connolly SJ. Prophylactic use of an implantable cardioverter defibrillator after acute myocardial infarction. N Engl J Med. 2004;351:2481–8.

    Article  CAS  PubMed  Google Scholar 

  36. Steinbeck G, Andresen D, Seidl K, Brachmann J, Hoffmann E, Wojciechowski D, Kornacewicz-Jach Z, Sredniawa B, Lupkovics G, Hofgartner F, Lubinski A, Rosenqvist M, Habets A, Wegscheider K, Senges J. Defibrillator implantation early after myocardial infarction. N Engl J Med. 2009;361:1427–36.

    Article  CAS  PubMed  Google Scholar 

  37. Chalil S, Stegemann B, Muhyaldeen S, et al. Intraventricular dyssynchrony predicts mortality and morbidity after cardiac resynchronization therapy: a study using cardiovascular magnetic resonance tissue synchronization imaging. J Am Coll Cardiol. 2007;50:243–52.

    Article  PubMed  Google Scholar 

  38. Yu CM, Lin H, Zhang Q, Sanderson JE. High prevalence of left ventricular systolic and diastolic asynchrony in patients with congestive heart failure and normal QRS duration. Heart. 2003;89:54–60.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Rao RK, Kumar UN, Schafer J, Viloria E, De Lurgio D, Foster E. Reduced ventricular volumes and improved systolic function with cardiac resynchronization therapy: a randomized trial comparing simultaneous biventricular pacing, sequential biventricular pacing, and left ventricular pacing. Circulation. 2007;115:2136–44.

    Article  PubMed  Google Scholar 

  40. Ritter P, Delnoy PP, Padeletti L, Lunati M, Naegele H, Borri-Brunetto A, Silvestre J. A randomized pilot study of optimization of cardiac resynchronization therapy in sinus rhythm patients using a peak endocardial acceleration sensor vs. standard methods. Europace. 2012;14:1324–33.

    Article  PubMed  Google Scholar 

  41. Holzmeister J, Leclercq C. Implantable cardioverter defibrillators and cardiac resynchronization therapy. Lancet. 2011;378(9792):722–30.

    Article  PubMed  Google Scholar 

  42. Perkiomaki JS, Ruwald AC, Kutyifa V, et al. Risk factors and the effect of cardiac resynchronization therapy on cardiac and non-cardiac mortality in MADIT-CRT. Europace. 2015;17(12):1816–22.

    Article  PubMed  Google Scholar 

  43. Bax JJ, Abraham T, Barold SS, et al. Cardiac resynchronization therapy. Part 1-issues before device implantation. J Am Coll Cardiol. 2005;46(12):2153–67.

    Article  PubMed  Google Scholar 

  44. Daubert JC, Leclercq C, Donal E, Mabo P. Cardiac resynchronisation therapy in heart failure: current status. Heart Fail Rev. 2006;11:147–54.

    Article  PubMed  Google Scholar 

  45. Cazeau S, Ritter P, Bakdach S, et al. Four chamber pacing in dilated cardiomyopathy. Pacing Clin Electrophysiol. 1994;17:1974–9.

    Article  CAS  PubMed  Google Scholar 

  46. Bakker P, Meijburg H, De Jonghe N, et al. Beneficial effects of biventricular pacing in congestive heart failure. Pacing Clin Electrophysiol. 1994;17:820 (abstract).

    Google Scholar 

  47. Kass DA. Zipes Lecture. Pathophysiology of cardiac dyssynchrny and resynchronization. Heart Rhythm. 2009;6(11):1660–5.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Cazeau S, Leclercq C, Lavergne T, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med. 2001;344:873–80.

    Article  CAS  PubMed  Google Scholar 

  49. Abraham WR, Fisher WG, Smith A, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002;346:1845–53.

    Article  PubMed  Google Scholar 

  50. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539–49.

    Article  CAS  PubMed  Google Scholar 

  51. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140–50.

    Article  CAS  PubMed  Google Scholar 

  52. Theuns DAMJ, Crozier IG, Barr CS, et al. Longevity of the subcutaneous implantable defibrillator: long-term follow-up of the European Regulatory Trial Cohort. Circ Arrhythm Electrophysiol. 2015;8(5):1159–63.

    Article  PubMed  Google Scholar 

  53. Weiss R, Knight BP, Gold MR, Leon AR, Herre JM, Hood M, Rashtian M, Kremers M, Crozier I, Lee KL, Smith W, Burke MC. Safety and efficacy of a totally subcutaneous implantable-cardioverter defibrillator. Circulation. 2013;128:944–53.

    Article  PubMed  Google Scholar 

  54. Lambiase PD, Barr C, Theuns DA, Knops R, Neuzil P, Johansen JB, Hood M, Pedersen S, Kääb S, Murgatroyd F, Reeve HL, Carter N, Boersma L, EFFORTLESS Investigators. Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry. Eur Heart J. 2014;35:1657–65.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Miller JD, Yousuf O, Berger R. The implantable cardioverter-defibrillator: an update. Trends Cardiovasc Med. 2015;25:606–11.

    Article  PubMed  Google Scholar 

  56. Ezekowitz JA, Rowe BH, Dryden DM, Hooton N, Vandermeer B, Spooner C, et al. Systematic review: implantable cardioverter defi brillators for adults with left ventricular systolic dysfunction. Ann Intern Med. 2007;147:251–62.

    Article  PubMed  Google Scholar 

  57. Reynolds MR, Cohen DJ, Kugelmass AD, Brown PP, Becker ER, Culler SD, et al. The frequency and incremental cost of major complications among medicare beneficiaries receiving implantable cardioverter-defibrillators. J Am Coll Cardiol. 2006;47:2493–7.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Lee DS, Krahn AD, Healey JS, Birnie D, Crystal E, Dorian P, Investigators of the Ontario ICD Database, et al. Evaluation of early complications related to de novo cardioverter defibrillator implantation insights from the Ontario ICD database. J Am Coll Cardiol. 2010;55:774–82.

    Article  PubMed  Google Scholar 

  59. Al-Khatib SM, Greiner MA, Peterson ED, Hernandez AF, Schulman KA, Curtis LH. Patient and implanting physician factors associated with mortality and complications after implantable cardioverterdefibrillator implantation, 2002-2005. Circ Arrhythm Electrophysiol. 2008;1:240–9.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Curtis JP, Luebbert JJ, Wang Y, et al. Association of physician certification and outcomes among patients receiving an implantable cardioverter-defibrillator. JAMA. 2009;301:1661–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Hsu JC, Varosy PD, Parzynski CS, Chaudrhy SI, Dewland TA, Curtis JP, Marcus GM. Procedure timing as a predictor of inhospital adverse outcomes from implantable cardioverter-defibrillator implantation: insights from the National Cardiovascular data Registry. Am Heart J. 2015;169(1):45–52.e3.

    Article  PubMed  Google Scholar 

  62. Dewland TA, Pellegrini CN, Wang YW, et al. Dual-chamber implantable cardioverter-defibrillator selection is associated with increased complication rates and mortality among patients enrolled in the NCDR implantable cardioverter-defibrillator registry. J Am Coll Cardiol. 2011;58(10):1007–13.

    Article  PubMed  Google Scholar 

  63. Hauser RG, Katsiyiannis WT, Gornick CC, Almquist AK, Kallinen LM. Deaths and cardiovascular injuries due to device-assisted implantable cardioverter-defibrillator and pacemaker lead extraction. Europace. 2010;12:395–401.

    Article  PubMed  Google Scholar 

  64. Brunner MP, Cronin EM, Duarte VE, Yu C, Tarakji KG, Martin DO, Callahan T, Cantillon DJ, Niebauer MJ, Saliba WI, Kanj M, Wazni O, Baranowski B, Wilkoff BL. Clinical predictors of adverse patient outcomes in an experience of more than 5000 chronic endovascular pacemaker and defibrillator lead extractions. Heart Rhythm. 2014;11:799–805.

    Article  PubMed  Google Scholar 

  65. Kleemann T, Becker T, Doenges K, et al. Annual rate of transvenous defibrillation lead defects in implantable cardioverter-defibrillators over a period of >10 years. Circulation. 2007;115(19):2474–80.

    Article  PubMed  Google Scholar 

  66. Persson R, Earley A, Garlitski AC, Balk EM, Uhlig K. Adverse events following implantable cardioverter defibrillator implantation: a systemic review. J Interv Card Electrophysiol. 2014;40:191–205.

    Article  PubMed  Google Scholar 

  67. Theuns D, Thornton AS, Klootwijk PJ, et al. Outcome in patients with an ICD incorporating cardiac resynchronization therapy: differences between primary and secondary prophylaxis. Eur J Heart Fail. 2005;7:1027–32.

    Article  PubMed  Google Scholar 

  68. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J. doi:10.1093/eurheartj/ehw128.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Electrophysiology, Erasmus Medical Center, Rotterdam, The Netherlands

    Mihran Martirosyan MD, Dominic A. M. J. Theuns PhD & Tamas Szili-Torok MD, PhD

  2. Department of Clinical Electrophysiology, Thoraxcenter, Erasmus MC, `s Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands

    Tamas Szili-Torok MD, PhD

Authors
  1. Mihran Martirosyan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dominic A. M. J. Theuns PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tamas Szili-Torok MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tamas Szili-Torok MD, PhD .

Editor information

Editors and Affiliations

  1. Emergency Clinical Hospital of Bucharest, UMF Carol Davila – Bucharest Emergency Clinical Hospital of Bucharest, Bucharest, Romania

    Maria Dorobanţu

  2. Department of Cardiology, University Heart Center Department of Cardiology, Zürich, Switzerland

    Frank Ruschitzka

  3. Section of Cardiovascular Diseases, University of Brescia Section of Cardiovascular Diseases, Brescia, Italy

    Marco Metra

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Martirosyan, M., Theuns, D.A.M.J., Szili-Torok, T. (2016). Devices for Heart Failure: Implantable Cardioverter Defibrillator. In: Dorobanţu, M., Ruschitzka, F., Metra, M. (eds) Current Approach to Heart Failure. Springer, Cham. https://doi.org/10.1007/978-3-319-45237-1_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-45237-1_13

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-45236-4

  • Online ISBN: 978-3-319-45237-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation